CRIS Curis, Inc.

2.61
+0  (2%)
Previous Close 2.55
Open 2.58
Price To book 12.32
Market Cap 370.33M
Shares 141,888,000
Volume 372,195
Short Ratio 3.97
Av. Daily Volume 517,563

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved January 30, 2012.
Vismodegib
Basal Cell Carcinoma
Phase 2 initial data due 1H 2017.
CUDC-907
Diffuse-large B-cell lymphoma (DLBCL)

Latest News

  1. Curis, Inc. – Value Analysis (NASDAQ:CRIS) : April 25, 2017
  2. Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : April 24, 2017
  3. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  4. Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting
  5. ETFs with exposure to Curis, Inc. : March 27, 2017
  6. Curis, Inc. :CRIS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  7. Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference
  8. Curis, Inc. :CRIS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  9. Markets Rally Late to Close in the Green: Today's Research Reports on Stocks to Watch Curis and Staples
  10. Curis, Inc. breached its 50 day moving average in a Bullish Manner : CRIS-US : March 10, 2017
  11. Edited Transcript of CRIS earnings conference call or presentation 9-Mar-17 1:30pm GMT
  12. Biotech Premarket Movers: Spectrum, BioCryst, Curis
  13. Curis reports 4Q loss
  14. Curis Reports Fourth Quarter and Year-End 2016 Financial Results
  15. Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017
  16. Curis to Present at the Cowen and Company 37th Annual Health Care Conference
  17. Top 3 Healthcare Penny Stocks for 2017
  18. Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference
  19. 3 Top Stocks Under $5